CN101274963A - 抗cd86人源化单克隆抗体 - Google Patents
抗cd86人源化单克隆抗体 Download PDFInfo
- Publication number
- CN101274963A CN101274963A CNA2008100431628A CN200810043162A CN101274963A CN 101274963 A CN101274963 A CN 101274963A CN A2008100431628 A CNA2008100431628 A CN A2008100431628A CN 200810043162 A CN200810043162 A CN 200810043162A CN 101274963 A CN101274963 A CN 101274963A
- Authority
- CN
- China
- Prior art keywords
- cell
- antibody
- seq
- sequence
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 49
- 239000003814 drug Substances 0.000 claims abstract description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims abstract description 7
- 238000000034 method Methods 0.000 claims description 22
- 101100230376 Acetivibrio thermocellus (strain ATCC 27405 / DSM 1237 / JCM 9322 / NBRC 103400 / NCIMB 10682 / NRRL B-4536 / VPI 7372) celI gene Proteins 0.000 claims description 20
- 241000699802 Cricetulus griseus Species 0.000 claims description 20
- 210000001672 ovary Anatomy 0.000 claims description 20
- 241000894006 Bacteria Species 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 9
- 238000012216 screening Methods 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 4
- 238000003151 transfection method Methods 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 229930193140 Neomycin Natural products 0.000 claims description 2
- 229960004927 neomycin Drugs 0.000 claims description 2
- 241000238631 Hexapoda Species 0.000 claims 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 abstract description 55
- 230000014509 gene expression Effects 0.000 abstract description 21
- 238000006243 chemical reaction Methods 0.000 abstract description 5
- 230000005847 immunogenicity Effects 0.000 abstract description 4
- 210000000056 organ Anatomy 0.000 abstract description 4
- 210000004978 chinese hamster ovary cell Anatomy 0.000 abstract description 3
- 230000004071 biological effect Effects 0.000 abstract description 2
- 239000012679 serum free medium Substances 0.000 abstract description 2
- 229940079593 drug Drugs 0.000 abstract 1
- 108020004414 DNA Proteins 0.000 description 35
- 239000007788 liquid Substances 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 29
- 210000001744 T-lymphocyte Anatomy 0.000 description 26
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 25
- 239000000243 solution Substances 0.000 description 17
- 239000006228 supernatant Substances 0.000 description 17
- 239000012530 fluid Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- 241000699666 Mus <mouse, genus> Species 0.000 description 14
- 238000013016 damping Methods 0.000 description 13
- 239000013612 plasmid Substances 0.000 description 13
- 238000005406 washing Methods 0.000 description 13
- 239000000427 antigen Substances 0.000 description 12
- 108091007433 antigens Proteins 0.000 description 12
- 102000036639 antigens Human genes 0.000 description 12
- 239000013604 expression vector Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 12
- 210000004408 hybridoma Anatomy 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 235000015097 nutrients Nutrition 0.000 description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 210000000612 antigen-presenting cell Anatomy 0.000 description 8
- 238000010790 dilution Methods 0.000 description 8
- 239000012895 dilution Substances 0.000 description 8
- 238000004321 preservation Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 230000004913 activation Effects 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000001556 precipitation Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 230000009182 swimming Effects 0.000 description 7
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 229920001917 Ficoll Polymers 0.000 description 5
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 5
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 description 5
- 238000001042 affinity chromatography Methods 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004443 dendritic cell Anatomy 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 229940126619 mouse monoclonal antibody Drugs 0.000 description 5
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102000007697 B7-2 Antigen Human genes 0.000 description 4
- 108010021800 B7-2 Antigen Proteins 0.000 description 4
- 101150001151 CD86 gene Proteins 0.000 description 4
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 4
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
- 239000007983 Tris buffer Substances 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical class N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 4
- 210000003719 b-lymphocyte Anatomy 0.000 description 4
- 239000006285 cell suspension Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000003248 secreting effect Effects 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 239000013049 sediment Substances 0.000 description 4
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
- 206010003445 Ascites Diseases 0.000 description 3
- 229940045513 CTLA4 antagonist Drugs 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 206010035226 Plasma cell myeloma Diseases 0.000 description 3
- 238000012300 Sequence Analysis Methods 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 230000001186 cumulative effect Effects 0.000 description 3
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 3
- 230000029087 digestion Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000011259 mixed solution Substances 0.000 description 3
- 201000000050 myeloid neoplasm Diseases 0.000 description 3
- 238000000734 protein sequencing Methods 0.000 description 3
- 238000005185 salting out Methods 0.000 description 3
- 238000007789 sealing Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000012410 DNA Ligases Human genes 0.000 description 2
- 108010061982 DNA Ligases Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 102000018997 Growth Hormone Human genes 0.000 description 2
- 108010051696 Growth Hormone Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108050007496 Shikimate kinase 2 Proteins 0.000 description 2
- 230000006044 T cell activation Effects 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 2
- 235000011130 ammonium sulphate Nutrition 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000011091 antibody purification Methods 0.000 description 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 102220369446 c.1274G>A Human genes 0.000 description 2
- 102220369445 c.668T>C Human genes 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000024835 cytogamy Effects 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 238000004043 dyeing Methods 0.000 description 2
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 2
- 239000013613 expression plasmid Substances 0.000 description 2
- 238000000684 flow cytometry Methods 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 230000004927 fusion Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000000122 growth hormone Substances 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 238000011081 inoculation Methods 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 238000005096 rolling process Methods 0.000 description 2
- 102220023258 rs387907548 Human genes 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035939 shock Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 238000001890 transfection Methods 0.000 description 2
- 230000001131 transforming effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000001291 vacuum drying Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 210000002845 virion Anatomy 0.000 description 2
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 102000053028 CD36 Antigens Human genes 0.000 description 1
- 108010045374 CD36 Antigens Proteins 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 101710203526 Integrase Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 241001045988 Neogene Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- MASVCBBIUQRUKL-UHFFFAOYSA-N POPOP Chemical compound C=1N=C(C=2C=CC(=CC=2)C=2OC(=CN=2)C=2C=CC=CC=2)OC=1C1=CC=CC=C1 MASVCBBIUQRUKL-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102000006382 Ribonucleases Human genes 0.000 description 1
- 108010083644 Ribonucleases Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010088160 Staphylococcal Protein A Proteins 0.000 description 1
- BDKZHNJTLHOSDW-UHFFFAOYSA-N [Na].CC(O)=O Chemical compound [Na].CC(O)=O BDKZHNJTLHOSDW-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000037189 immune system physiology Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- PHTQWCKDNZKARW-UHFFFAOYSA-N isoamylol Chemical compound CC(C)CCO PHTQWCKDNZKARW-UHFFFAOYSA-N 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005374 membrane filtration Methods 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 101150091879 neo gene Proteins 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 238000000197 pyrolysis Methods 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 238000012882 sequential analysis Methods 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- RWVGQQGBQSJDQV-UHFFFAOYSA-M sodium;3-[[4-[(e)-[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfonatophenyl)methyl]azaniumylidene]-2-methylcyclohexa-2,5-dien-1-ylidene]methyl]-n-ethyl-3-methylanilino]methyl]benzenesulfonate Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C)C=C1 RWVGQQGBQSJDQV-UHFFFAOYSA-M 0.000 description 1
- 210000004988 splenocyte Anatomy 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003805 vibration mixing Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Landscapes
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100431628A CN101274963B (zh) | 2008-03-07 | 2008-03-07 | 抗cd86人源化单克隆抗体 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100431628A CN101274963B (zh) | 2008-03-07 | 2008-03-07 | 抗cd86人源化单克隆抗体 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101274963A true CN101274963A (zh) | 2008-10-01 |
CN101274963B CN101274963B (zh) | 2011-11-16 |
Family
ID=39994848
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100431628A Active CN101274963B (zh) | 2008-03-07 | 2008-03-07 | 抗cd86人源化单克隆抗体 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101274963B (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102628763A (zh) * | 2012-03-14 | 2012-08-08 | 中华人民共和国天津出入境检验检疫局 | 一种用于高效率洗脱口腔拭子中活性抗体的试剂和洗脱方法 |
CN107099505A (zh) * | 2017-04-15 | 2017-08-29 | 河北省农林科学院粮油作物研究所 | 抗FtsH2蛋白单克隆抗体及其应用 |
-
2008
- 2008-03-07 CN CN2008100431628A patent/CN101274963B/zh active Active
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102628763A (zh) * | 2012-03-14 | 2012-08-08 | 中华人民共和国天津出入境检验检疫局 | 一种用于高效率洗脱口腔拭子中活性抗体的试剂和洗脱方法 |
CN107099505A (zh) * | 2017-04-15 | 2017-08-29 | 河北省农林科学院粮油作物研究所 | 抗FtsH2蛋白单克隆抗体及其应用 |
CN107099505B (zh) * | 2017-04-15 | 2019-11-12 | 河北省农林科学院粮油作物研究所 | 抗FtsH2蛋白单克隆抗体及其应用 |
Also Published As
Publication number | Publication date |
---|---|
CN101274963B (zh) | 2011-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107217042A (zh) | 一种生产无岩藻糖基化蛋白的基因工程细胞系及其建立方法 | |
CN101851291B (zh) | 一种抗人baff单克隆抗体的重链和轻链可变区 | |
CN108373504A (zh) | Cd24特异性抗体和抗cd24-car-t细胞 | |
CN113699118B (zh) | 一种杂交瘤细胞株及其产生的抗体和应用 | |
CN103073644A (zh) | 特异性抗小鼠tigit的单克隆抗体及其制备方法、鉴定及应用 | |
CN102816235B (zh) | 一种抗常用苏云金芽孢杆菌CryI单克隆抗体杂交瘤的制备方法及其单克隆抗体的应用 | |
CN109385403A (zh) | 靶向gpc3的car nk细胞 | |
CN108004215B (zh) | 杂交瘤细胞株及其产生的抗体和制备方法 | |
CN109422815A (zh) | 双特异性嵌合抗原受体c-Met/PD-1 scFv-CAR-T及其构建方法和应用 | |
CN109678963A (zh) | 一种靶向cd24且激活nk细胞的双特异性抗体的制备及其应用 | |
US9725521B2 (en) | Human-derived insecticidal gene and insecticidal peptide encoded thereby and application thereof | |
CN101215329B (zh) | 可溶性人程序性死亡蛋白-1-IgV及其制备方法 | |
CN103910796B (zh) | 一种全人源抗狂犬病毒的中和抗体 | |
CN102690789A (zh) | 分泌破伤风外毒素单克隆抗体的杂交瘤细胞株及由其制备的单克隆抗体、Fab抗体与应用 | |
CN109777785B (zh) | 杂交瘤细胞株及其应用 | |
CN101274963B (zh) | 抗cd86人源化单克隆抗体 | |
CN113481170A (zh) | 杂交瘤细胞株及其产生的抗体和制备方法 | |
CN109988752A (zh) | 一种抗人b7-h4单克隆抗体及其制备和应用 | |
del Rio et al. | Immunotherapeutic targeting of LIGHT/LTβR/HVEM pathway fully recapitulates the reduced cytotoxic phenotype of LIGHT-deficient T cells | |
CN116396402A (zh) | 一种嵌合抗原受体、嵌合抗原受体修饰的免疫应答细胞及其构建方法和应用 | |
CN116199781A (zh) | 一种靶向cd22的单域抗体、嵌合抗原受体及其应用 | |
CN114426955B (zh) | 抗虫蛋白Cry 3Bb杂交瘤细胞株及其产生的抗体和应用 | |
CN101544697A (zh) | 融合蛋白TT-B7-H4IgV及其制备方法和用途 | |
CN114075285B (zh) | 抗人cd38人源化单克隆抗体及其应用 | |
CN109970859A (zh) | Glypican-3特异性抗体及其特异性CAR-T细胞 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Lu Xiaobing Inventor after: Zheng Yong Inventor after: Feng Dongxiao Inventor before: Zheng Yong Inventor before: Feng Dongxiao Inventor before: Lu Xiaobing |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: ZHENG YONG FENG DONGXIAO LU XIAOBING TO: LU XIAOBING ZHENG YONG FENG DONGXIAO |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160615 Address after: 264400, Nanhai District, Shandong City, Longhai Province, Weihai Road East, sunny northbound Patentee after: Weihai Yong Dong biological new medicine research and Development Co Ltd Address before: 201203 Shanghai city Pudong New Area Tong Road 618 Lane No. 48 Room 601 Patentee before: Lu Xiaobing Patentee before: Zheng Yong Patentee before: Feng Dongxiao |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20191114 Address after: 264207 Binhai New Area, Weihai, Shandong Province, north coast, Longhai Road East Patentee after: Co., Ltd of blue research institute for economics of Weihai City Address before: 264400, Nanhai District, Shandong City, Longhai Province, Weihai Road East, sunny northbound Patentee before: Weihai Yong Dong biological new medicine research and Development Co Ltd |